Sharekhan

#SharekhanFNA L&T Technology Q4FY22 results: Revenue missed, while margin beat estimates; growth guidance (13.5-15.… https://t.co/ug6NbYlGMA #SharekhanFNA

#SharekhanFNA Tata Elxsi Q4FY22 results: revenue beat, margins in-line; CC revenue grew 7.4% qoq & 30.9% yoy; EBITD… https://t.co/fMZgVBuzB3 #SharekhanFNA

#SharekhanFNA Mastek Q4FY22 results: in-line revenue growth; CC revenue grew 5.3% qoq; EBIT margin declined by 50bp… https://t.co/pvTNm5fz6G #SharekhanFNA

#SharekhanFNA #SharekhanResearch retains Buy rating on #DrReddys (PT Rs5550) concerns to slow down US sales growth… https://t.co/VGbz2DidY6 #SharekhanFNA #SharekhanResearch #DrReddys

#SharekhanFNA #PVR & #Inox Leisure announced merger of entities; merger ratio is 3 shares of PVR for every 10 share… https://t.co/gKGmw5I04d #SharekhanFNA #PVR #Inox

#SharekhanFNA #SharekhanResearch reiterates Buy rating on #Divis (PT Rs 5620) charts plan focusing on 6 pillars to… https://t.co/d6eU3dztJp #SharekhanFNA #SharekhanResearch #Divis

#SharekhanFNA #SharekhanResearch #Q3FY22 Pharma Review- weak qtr, strng gwth in India bizz, US gwth muted while cos… https://t.co/AdYDkj4Qai #SharekhanFNA #SharekhanResearch #Q3FY22

#SharekhanFNA #SharekhanResearch retains Buy rating on #Divis (PT Rs 5620) #Q3FY22 strng qtr, rslts ahead of est; C… https://t.co/svLM1XfNwC #SharekhanFNA #SharekhanResearch #Divis #Q3FY22

#SharekhanFNA #SharekhanResearch retains Hold on #StridesPharma (PT Rs450) #Q3FY22 was another weak qtr; near term… https://t.co/8nI3HniDms #SharekhanFNA #SharekhanResearch #StridesPharma #Q3FY22